Meeting
2016 ASCO Annual Meeting
Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
Authors
Georgina V. Long
Melanoma Institute Australia and The University of Sydney, North Sydney, Australia
Georgina V. Long , Reinhard Dummer , Antoni Ribas , Igor Puzanov , Ari VanderWalde , Robert Hans Ingemar Andtbacka , Olivier Michielin , Anthony J. Olszanski , Josep Malvehy , Jonathan S. Cebon , Eugenio Fernandez , John M. Kirkwood , Thomas Gajewski , Christine K. Gause , Lisa Chen , Kevin Gorski , Abraham Anderson , David Ross Kaufman , Jeffrey Chou , F. Stephen Hodi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02263508
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9568)
DOI
10.1200/JCO.2016.34.15_suppl.9568
Abstract #
9568
Poster Bd #
173
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).
First Author: Georgina V. Long
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial.
First Author: Robin Kate Kelley
Poster
2018 ASCO Annual Meeting
Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).
First Author: Siwen Hu-Lieskovan